Niagen Bioscience, Inc. is a Nasdaq-listed bioscience and healthy-aging company that develops and sells products based on nicotinamide riboside (NR), a NAD+ precursor sold under the "Niagen" brand. The company, formerly known as ChromaDex, is a leader in the science of raising cellular NAD+ levels, a coenzyme tied to energy metabolism and DNA repair. As of the latest close, shares trade near $3.29, down roughly two-thirds from the $10.52 level reached in late 2025.
The $10 price target has emerged as the most widely discussed objective because it sits at the convergence of three things: a round psychological milestone, the stock's prior major high, and the consensus view of Wall Street analysts. For a stock that has been cut by more than 60% over the past year, the question of whether it can reclaim $10 is essentially a question of whether the company can restore investor confidence and return to its former highs.
Niagen Bioscience is a micro-cap company with a market value of roughly $254 million. It generates trailing twelve-month revenue of approximately $129 million and is profitable, with a trailing price-to-earnings (P/E) ratio near 17. The company's financial position is a clear strength: it holds about $66.6 million in cash against minimal debt of around $2.3 million, and its gross margin has held near 64%.
However, growth has slowed. Second-quarter 2026 revenue of roughly $29.8 million declined modestly year over year, and quarterly earnings growth turned sharply negative. The stock's elevated beta of about 2.10 underscores its sensitivity to broader market swings and its characteristically high small-cap volatility.
Several factors could support a move toward $10. First, the company maintains a strong intellectual-property position, with more than 90 issued and pending patents. A U.S. District Court ruling in Delaware recently upheld the enforceability of a key nicotinamide riboside patent, reinforcing the company's competitive moat.
Second, Niagen Bioscience is expanding beyond supplements into higher-margin and higher-visibility categories. The launch of the Niagen Plus injectable franchise, an at-home telehealth platform, and a partnership with OneSpaWorld to offer IV treatments on luxury cruise ships all broaden its addressable market. The board also doubled its share repurchase authorization to $20 million, signaling confidence in the company's valuation.
Third, the company has announced its first investigational drug candidate, NB4168, through its wholly owned NAD Pharmaceuticals subsidiary, targeting accelerated-aging and rare genetic diseases, with first-in-human studies expected in 2027. A successful clinical readout could transform how the market values the company.
The obstacles are substantial. Decelerating revenue growth and shrinking quarterly profits suggest the core supplement business has lost momentum. Regulatory shifts add further uncertainty: the FDA's reversal on NMN, a competing NAD+ precursor, has introduced new competitive dynamics into the category, and the company's ability to sustain demand in a shifting market remains unproven.
Drug development is also a long-term, high-risk endeavor. NB4168 is years away from potential commercialization, and clinical-stage setbacks are common. For a stock trading near $3.29, a return to $10 would require not only a recovery in fundamentals but also a dramatic change in investor sentiment toward a company that has disappointed shareholders over the past year.
Wall Street remains optimistic despite the stock's decline. According to S&P Global data, six analysts carry a consensus rating of "Strong Buy" with an average twelve-month price target of about $12.08. More recent, modestly reduced targets cluster tightly around $10: Canaccord Genuity and Roth MKM both hold $10 targets, H.C. Wainwright and Ladenburg Thalmann stand at $11, and Freedom Capital initiated coverage with a $9 target. The lowest current target of $8.50 and the highest of $22 highlight a wide dispersion, but the center of gravity sits squarely at the $10 level investors are asking about.
From a technical-analysis perspective, the $2.87 52-week low is the critical support level that must hold for the bullish case to remain intact. On the upside, $10.52 marks the prior major high and the primary resistance zone, meaning the $10 target lies just beneath a ceiling where heavy supply previously emerged. Reclaiming that area would require a decisive breakout accompanied by a sustained shift in demand, rather than a brief speculative spike.
Traders tracking volatile, event-driven names like NAGE often supplement their research with automated tools. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders discover opportunities, monitor existing positions, and identify shifting market trends more efficiently. Investors seeking an additional layer of objective, data-driven insight may find value in incorporating such tools into their decision-making process.
Reaching $10 remains a demanding proposition for Niagen Bioscience. The target aligns with the analyst consensus and the stock's former high, giving it credibility as a meaningful objective, but it implies a roughly 200% advance from current levels. The company's cash-rich balance sheet, durable patent portfolio, and pharmaceutical optionality provide a plausible foundation for a recovery, while decelerating growth, regulatory uncertainty, and clinical-development risk present real obstacles.
Investors should monitor quarterly revenue trends, the adoption of the Niagen Plus injectable franchise, any regulatory developments affecting the NAD+ category, and progress on the NB4168 clinical program. Whether the stock can realistically reach $10 will ultimately depend on whether the company can reignite growth and convince the market to value it as more than a struggling supplement maker.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NAGE has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAGE jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To NAGE | 1D Price Change % | ||
|---|---|---|---|---|
| NAGE | 100% | -1.89% | ||
| AXON - NAGE | 43% Loosely correlated | +6.15% | ||
| TRDA - NAGE | 38% Loosely correlated | -1.78% | ||
| AMRN - NAGE | 35% Loosely correlated | +0.07% | ||
| CYTK - NAGE | 35% Loosely correlated | +2.81% | ||
| ENGN - NAGE | 34% Loosely correlated | -3.17% | ||
More | ||||
| Ticker / NAME | Correlation To NAGE | 1D Price Change % |
|---|---|---|
| NAGE | 100% | -1.89% |
| Food: Major Diversified industry (63 stocks) | 2% Poorly correlated | -0.90% |